Cargando…
Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite intensive treatment, the prognosis for patients with GBM remains grim with a median survival of only 14.6 months. Immunotherapy has emerged as a promising approach for treating many cancers and aff...
Autores principales: | Jackson, Christopher, Ruzevick, Jacob, Phallen, Jillian, Belcaid, Zineb, Lim, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235820/ https://www.ncbi.nlm.nih.gov/pubmed/22190972 http://dx.doi.org/10.1155/2011/732413 |
Ejemplares similares
-
Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
por: Nicholas, Sarah, et al.
Publicado: (2013) -
The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014) -
Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017) -
Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022) -
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme
por: Xu, Xun, et al.
Publicado: (2012)